Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 21 - 30 of 243
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Epididymal Calchlorin
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: Parsemus Foundation
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 51 - 60 of 70
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
PC6
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Vindico NanoBio Technology Inc.
Development Stage: Lead Optimization
Alternative Name: PGE2
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, Bayer HealthCare
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Other
Development Stage: Compound ID/Selection
Alternative Name: Retinoic acid receptor (RAR) antagonists
Target
User: Male
Hormonal: No
Duration Type: Short-acting
Developer: NICHD, Columbia University, University of Washington, University of Minnesota
Development Stage: Target Validation
Alternative Name: l-CDB-4022
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Development Stage: Lead Optimization
Alternative Name: Serum- and Glucocorticoid-Regulated Kinase
Target
User: Female
Hormonal: No
Developer: CONRAD, Imperial College, London
Development Stage: Target Identification

Pages

Displaying 11 - 20 of 121
Alternative Name: Epididymal Calchlorin
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: Parsemus Foundation
Development Stage: Pre-clinical
Alternative Name: Capronor Biodegradable Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: RTI International, NICHD
Development Stage: Phase II
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Rajasthan, India
Development Stage: Phase I
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: CEMAG
Development Stage: Pre-clinical
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Phase II
User: Female
Hormonal: Yes
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Regulatory
Alternative Name: BioRings Intravaginal Ring
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: BioRings, Weill Cornell Medical College, QPharma
Development Stage: Pre-clinical
Alternative Name: Carboxy Terminus Peptide of β-human chorionic gonadotropin
User: Female
Hormonal: No
Developer: WHO, Talwar Research Foundation
Development Stage: Phase II
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral, Subdermal
Developer: University of Edinburgh
Development Stage: Phase II

Pages

Displaying 41 - 50 of 52
Alternative Name: MCR-165, Medicated Contraceptive Ring-165
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed
Alternative Name: Depo-subQ + Uniject
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Pfizer, PATH, USAID
Development Stage: SRA/WHO PQ Approved
Alternative Name: Flomax
User: Male
Hormonal: No
Duration Type: Pericoital
Delivery Method: Oral
Development Stage: SRA/WHO PQ Approved
Alternative Name: IUD HBCu375/MCu375 and TCu380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tianjin Medical Instrument Factory
Development Stage: Marketed
Alternative Name: Triclovera; OSKB -1
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: PT. Tunggal Idaman Abdi
Development Stage: Marketed
Alternative Name: LNG Contraceptive IUS 12 (LCS12)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council, Theramex, Rockefeller Foundation
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Development Stage: Marketed
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed

Pages

CSV